These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 9049230)

  • 1. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy.
    Kurosaki M; Enomoto N; Murakami T; Sakuma I; Asahina Y; Yamamoto C; Ikeda T; Tozuka S; Izumi N; Marumo F; Sato C
    Hepatology; 1997 Mar; 25(3):750-3. PubMed ID: 9049230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa.
    Zeuzem S; Lee JH; Roth WK
    Hepatology; 1997 Mar; 25(3):740-4. PubMed ID: 9049228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.
    Enomoto N; Sakuma I; Asahina Y; Kurosaki M; Murakami T; Yamamoto C; Ogura Y; Izumi N; Marumo F; Sato C
    N Engl J Med; 1996 Jan; 334(2):77-81. PubMed ID: 8531962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
    Saito T; Ito T; Ishiko H; Yonaha M; Morikawa K; Miyokawa A; Mitamura K
    Am J Gastroenterol; 2003 Jun; 98(6):1377-83. PubMed ID: 12818284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection.
    Chayama K; Tsubota A; Kobayashi M; Okamoto K; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Suzuki Y; Murashima N; Ikeda K; Kumada H
    Hepatology; 1997 Mar; 25(3):745-9. PubMed ID: 9049229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of the efficacy of intravenous natural interferon-beta treatment in chronic hepatitis C.
    Fukutomi T; Fukutomi M; Iwao M; Watanabe H; Tanabe Y; Hiroshige K; Kinukawa N; Nakamuta M; Nawata H
    Med Sci Monit; 2000; 6(4):692-8. PubMed ID: 11208393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C.
    Karino Y; Toyota J; Sugawara M; Higashino K; Sato T; Ohmura T; Suga T; Okuuchi Y; Matsushima T
    Am J Gastroenterol; 1997 Jan; 92(1):61-5. PubMed ID: 8995939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus.
    Nakamura H; Ogawa H; Kuroda T; Yamamoto M; Enomoto H; Kishima Y; Yoshida K; Ito H; Matsuda M; Noguchi S
    Hepatogastroenterology; 2002; 49(47):1373-6. PubMed ID: 12239945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Association between NS5A gene sequence and response to interferon therapy in chronic hepatitis C patients in Shanghai].
    Hu Y; Tang M; Jiang W; Wu Y; Yuan Z; Wen Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Jun; 16(2):114-8. PubMed ID: 12196819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.
    Martinot-Peignoux M; Marcellin P; Pouteau M; Castelnau C; Boyer N; Poliquin M; Degott C; Descombes I; Le Breton V; Milotova V
    Hepatology; 1995 Oct; 22(4 Pt 1):1050-6. PubMed ID: 7557850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy for most common European hepatitis C virus genotypes.
    Frangeul L; Cresta P; Perrin M; Lunel F; Opolon P; Agut H; Huraux JM
    Hepatology; 1998 Dec; 28(6):1674-9. PubMed ID: 9828234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
    Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
    Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon.
    Kobayashi M; Watanabe K; Ishigami M; Murase K; Ito H; Ukai K; Yano M; Takagi K; Hattori M; Kakumu S; Yoshioka K
    Am J Gastroenterol; 2002 Apr; 97(4):988-98. PubMed ID: 12003437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis.
    Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Med Virol; 2005 Apr; 75(4):550-8. PubMed ID: 15714492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative evaluation of serum HCV RNA by Roche Monitor Assay. Versions 1.0 and 2.0; as a predictive marker of subsequent response to IFN therapy].
    Takenokuchi M; Yasuda C; Nakamachi Y; Mukai M; Yoon S; Kondoh S; Kumagai S
    Rinsho Byori; 2002 Apr; 50(4):392-7. PubMed ID: 12014019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in viral kinetics between genotypes 1 and 2 of hepatitis C virus after single administration of standard interferon-alpha.
    Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kanamori A; Atsumi H; Takagi M; Nakano S; Arakawa T; Fujimori M
    J Med Virol; 2009 Aug; 81(8):1354-62. PubMed ID: 19551828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients.
    Missale G; Cariani E; Lamonaca V; Ravaggi A; Rossini A; Bertoni R; Houghton M; Matsuura Y; Miyamura T; Fiaccadori F; Ferrari C
    Hepatology; 1997 Sep; 26(3):792-7. PubMed ID: 9303515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleotide sequence variations in the internal ribosome entry site of hepatitis C virus-1b: no association with efficacy of interferon therapy or serum HCV-RNA levels.
    Yamamoto C; Enomoto N; Kurosaki M; Yu SH; Tazawa J; Izumi N; Marumo F; Sato C
    Hepatology; 1997 Dec; 26(6):1616-20. PubMed ID: 9398006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Structural analysis of the PKR-binding region of HCV 1b samples from patients with chronic hepatitis C and the correlation with IFN-sensitivity].
    Gervain J; Czibula A; Simon J; Kalmár T
    Orv Hetil; 2003 Jun; 144(24):1179-84. PubMed ID: 12866147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.